C3 Glomerulopathy
Nephrology·MeSH: Glomerulonephritis, IGA
Prevalence
0.5 / 100K
8 drugs in development·6 companies·9 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| lnp023 | Novartis AG (NVS) |
Phase 2(4)
Preclinical(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ARO-C3 | ARROWHEAD PHARMACEUTICALS, INC. (ARWR) |
Phase 4(1)
| Drug | Company |
|---|---|
| Avacopan | AMGEN INC (AMGN) |
Compare drugs
Frequently asked questions
How many drugs are in development for C3 Glomerulopathy?
BioSniper tracks 8 drugs in development for C3 Glomerulopathy across 6 companies.
How many clinical trials target C3 Glomerulopathy?
There are 9 clinical trials targeting C3 Glomerulopathy tracked by BioSniper.
What is the prevalence of C3 Glomerulopathy?
The estimated prevalence of C3 Glomerulopathy is approximately 0.5 per 100,000 population.
Deep-dive into C3 Glomerulopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis